Drugs / MT027
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06912152 | May 2025 → Oct 2028 expected | peritoneal neoplasm | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT06737146 | Jan 2025 → Jun 2026 overdue | glioma | Suzhou Maximum Bio-tech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06742593 | Jan → Dec 2025 overdue | brain cancer | Suzhou Maximum Bio-tech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06726564 | May 2024 → May 2026 overdue | malignant pleural mesothelioma | Suzhou Maximum Bio-tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07386002 | Jun 2026 → Dec 2028 expected | IDH-wildtype glioblastoma | T-MAXIMUM Pharmaceutical Inc | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07004647 | Mar 2025 → Oct 2028 expected | peritoneal neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT027 | “MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors” NCT07004647 ↗ |
| Modality | Cell therapy | “MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells” NCT06726564 ↗ |
| Route | Other | “MT027 will be given intrapleural injection via pleural cavity puncture” NCT06726564 ↗ |